Company intelligence / Profile preview

Senya Therapeutics

Bicester, Oxon, United Kingdomsenyatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a lead molecule, STX-002, that inhibits the activity of LRG1 and has successfully demonstrated its efficacy in a range of translational preclinical models. These results have shown that the compound is safe and well-tolerated.

Therapeutic areas: NephrologyOncologyEndocrinologyImmunologyCardiovascularOphthalmologyNeurology
Modalities: Biologics
Industry: Biotech

Drug pipeline

1 asset

LRG1 function-blocking antibody

Pre-clinical

Indications: Metastatic colorectal cancer, Liver metastases

Beyond the preview

Go deeper on Senya Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senya Therapeutics.

Explore the full profile